Triggering CD40 on endothelial cells contributes to tumor growth

Area of Science:

• Immunology
• Oncology
• Vascular Biology

Background:

• Inflammatory cells influence tumor progression.
• CD40 is a key molecule in adaptive immune responses.
• Its role in mammary carcinogenesis is not fully understood.

Purpose of the Study:

• Investigate the role of CD40 in mammary carcinogenesis using BALB/NeuT transgenic mice.
• Determine if CD40 deficiency impacts tumor development and angiogenesis.
• Identify the cellular source of CD40L in this model.

Main Methods:

• Generated CD40-knockout (CD40-KO) BALB/NeuT mice.
• Performed bone marrow transplantation experiments.
• Analyzed tumor vasculature and treated mice with clopidogrel.

Main Results:

• CD40-KO/NeuT mice exhibited delayed tumor onset and reduced tumor multiplicity.
• CD40 deficiency impaired tumor angiogenesis, resulting in poorly organized vasculature.
• Clopidogrel treatment in wild-type mice mimicked the anti-tumor effects of CD40 deficiency.
• Bone marrow-derived cells were not responsible for the reduced tumorigenicity.

Conclusions:

• CD40 expressed by endothelial cells plays a role in tumor angiogenesis.
• Activated platelets are a significant source of CD40L, contributing to mammary tumor growth.
• Targeting the CD40/CD40L pathway, particularly via platelet inhibition, may offer therapeutic strategies for mammary cancer.